Balaji Amines LimitedQ1 FY27 Results & Financial Update
Balaji Amines Limited: Q1 FY27 consolidated results and company financials – revenue ₹461.45 Cr, PAT ₹78.12 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Balaji Amines price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Balaji Amines Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Balaji Amines commenced FY27 with a strong operational and financial performance on a consolidated basis, supported by improving demand across key end-user industries and resilient operating margins.
Total consolidated revenue for the first quarter ended 30 June 2026 stood at INR 461.45 crore, while profit before tax reached INR 106.20 crore.
Reported profit after tax for Q1 FY27 stood at INR 78.12 crore, translating to basic earnings per share of INR 23.13 for the quarter.
The company achieved a major strategic milestone during the period with the successful commercial commissioning of India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant at its Unit IV facility in Solapur.
Management noted that the newly operational DME facility establishes domestic exposure to clean fuel, LPG blending, and aerosol propellant applications, furthering the company's import substitution objectives.
Other ongoing expansion projects, including N-Methyl Morpholine (NMM) and Acetonitrile (ACN) capacities, remain on track for commissioning within FY27, backed by healthy order pipelines and disciplined capital execution.
The standalone core chemical business maintained its debt-free balance sheet status, providing robust financial stability as the enterprise executes its ongoing capital expenditure cycle.
01 · Business model
What does Balaji Amines do?
Balaji Amines Limited is a prominent Indian manufacturer of aliphatic amines, specialty chemicals, and derivatives, operating multiple manufacturing units strategically located across Solapur in Maharashtra and Telangana.
The company's integrated production model encompasses core aliphatic amines such as methylamine and ethylamine, amine derivatives like DMAC and DMAHCL, and advanced specialty chemicals including morpholine, acetonitrile, NMP, and DMC.
Its products serve critical and growing end markets such as pharmaceuticals, agrochemicals, EV batteries, paints and resins, animal feeds, and industrial applications both domestically and across more than 50 international countries.
Balaji Amines also operates a hospitality division through its subsidiary-owned five-star property, Hotel Balaji Sarovar Premiere in Solapur, providing a diversified revenue stream alongside its core chemical operations.
02 · Historical context
What shaped the business before this quarter
Established in 1988, Balaji Amines has built over 35 years of manufacturing expertise, developing in-house R&D processes for aliphatic amines.
Balaji Speciality Chemicals Limited (BSCL) commenced commercial operations in 2019 as a 55% subsidiary to drive high-value specialty chemical import substitution.
The company commenced operations at Hotel Balaji Sarovar Premiere in October 2013, investing INR 110 crore via a mix of debt and equity into the Solapur property.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹461.45 Cr |
| Total income | ₹461.45 Cr |
| Profit before tax | ₹106.20 Cr |
| Profit after tax | ₹78.12 Cr |
| EPS | ₹23.13 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 16.9% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 23.0% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Management reported that top-line performance was supported by strengthening demand across core end-user segments like pharmaceuticals, agrochemicals, and industrial applications.
Revenue generation remained anchored by the core aliphatic amines segment, value-added amine derivatives, and high-value specialty chemical portfolios.
What drove margins
Total raw material consumption stood at INR 252.88 crore for the quarter, managed within an integrated vertical chain that ensures cost efficiency and supply consistency.
EBITDA margin remained healthy at 26.31% (INR 121.40 crore), benefiting from operational efficiencies and scale benefits across key manufacturing plants.
05 · Demand, customers & order book
Where demand is coming from
Balaji Amines supplies leading global and domestic industry participants across pharma, agrochemicals, and industrial sectors, backed by a healthy order pipeline.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Hotel Balaji Sarovar Premiere generated INR 7.99 crore in revenue during Q1 FY27, constituting approximately 1.73% of total consolidated revenue with an average occupancy rate of 68% and an ARR of INR 5,242.
Geography and market mix
The company serves over 65 international clients and exports its specialty chemical products to more than 50 countries worldwide.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company successfully commissioned India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant at Unit IV in Solapur during Q1 FY27.
Consolidated manufacturing operations span a total licensed capacity base across Solapur and Telangana facilities, complemented by BSCL's specialty units.
Projects, capex and execution
Greenfield and brownfield expansion projects at subsidiary BSCL—covering HCN, Sodium Cyanide, EDA derivatives, and EDTA plants—are progressing as planned.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The enterprise is actively transitioning from a standard amines producer into a comprehensive specialty chemicals platform focused on import substitution and clean energy applications.
09 · Reported developments
What changed operationally
Demonstrated robust profitability with PBT at INR 106.20 crore and PAT at INR 78.12 crore for Q1 FY27.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Ongoing expansion capital expenditures across consolidated units and subsidiary projects continue to be funded largely through internal accruals and existing financial reserves.
Capital allocation & funding
The standalone business remains debt-free, maintaining a strong net worth profile that provides significant downside protection and balance sheet flexibility.
11 · Management guidance & targets
What management is targeting from here
Management guided for consolidated volume growth of 10% to 15% in FY27, with medium-term volume growth projected at 20% to 30%.
Management targeted an EBITDA margin of 22% to 23% for FY27, comparing favorably against ~20% achieved in FY26.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Hotel Division Savings
The Solapur five-star hotel investment of INR 110 crore has historically resulted in substantial cash flow savings and steady regional hospitality contributions.
13 · Key Q&A
The quarter, answered directly
What does Balaji Amines do?
Balaji Amines Limited is a prominent Indian manufacturer of aliphatic amines, specialty chemicals, and derivatives, operating multiple manufacturing units strategically located across Solapur in Maharashtra and Telangana.
What is the clearest takeaway from Q1 FY27?
Balaji Amines commenced FY27 with a strong operational and financial performance on a consolidated basis, supported by improving demand across key end-user industries and resilient operating margins.
What drove revenue or demand?
Management reported that top-line performance was supported by strengthening demand across core end-user segments like pharmaceuticals, agrochemicals, and industrial applications.
What mattered most for margins or profitability?
Total raw material consumption stood at INR 252.88 crore for the quarter, managed within an integrated vertical chain that ensures cost efficiency and supply consistency.
What changed operationally beyond the headline numbers?
The company successfully commissioned India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant at Unit IV in Solapur during Q1 FY27.
What is management guiding or targeting from here?
Management guided for consolidated volume growth of 10% to 15% in FY27, with medium-term volume growth projected at 20% to 30%.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
BSCL Subsidiary Project Progress: Track the execution milestone progress of BSCL's greenfield HCN, Sodium Cyanide, and EDTA plants targeted for completion by end-FY27.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.